ABC2's Max Wallace To Serve On Pediatric Brain Tumor Foundation's New Research Advisory Network

September 11, 2014

Max Wallace, CEO of Accelerate Brain Cancer Cure, has been named a member of the Pediatric Brain Tumor Foundation's new Research Advisory Network (RAN). RAN members will contribute insights to help shape PBTF’s funding priorities and evaluate the impact of its research investment on the lives of children diagnosed with a brain tumor, as well as on the disease that threatens them.

The 17 volunteer members of the panel are drawn from medical centers, a research institution, a brain tumor nonprofit and the pharmaceutical industry. They will serve a three-year, renewable term.

The experts are:

• Suzanne Baker, PhD, St. Jude Children’s Research Hospital

• Jill Barnholtz-Sloan, PhD, Case Western Reserve University

• Oren Becher, MD, Duke University School of Medicine

• Tom Curran, PhD, FRS, The Children’s Hospital of Philadelphia

• Yancey Gillespie, PhD, University of Alabama at Birmingham

• Gerald Grant, MD, Stanford School of Medicine

• Nalin Gupta, MD, PhD, UCSF Benioff Children’s Hospital

• Mark Kieran, MD, PhD, Dana-Farber Cancer Institute and Boston Children’s Hospital

• Duane Mitchell, MD, PhD, University of Florida

• Michelle Monje-Deisseroth, MD, PhD, Stanford School of Medicine

• Sabine Mueller, MD, PhD, UCSF Benioff Children’s Hospital

• Roger Packer, MD, Children’s National Health System

• Will Parsons, MD, PhD, Texas Children’s Hospital

• Raphael Rousseau, MD, PhD, Genentech

• James Rutka, MD, PhD, FRCSC, FACS, FAAP, Hospital for Sick Children

• Max Wallace, Accelerate Brain Cancer Cure

• Robert Wechsler-Reya, PhD, Sanford-Burnham Medical Research Institute

“The members of the Research Advisory Network, or RAN, will provide highly informed perspectives on the biomedical research enterprise,” said Dr. Joanne Salcido, vice president of research and family support. “It is an important facet of the PBTF’s partnership with the research community.”

"PBTF is a leader in the fight against childhood brain cancer," said Max Wallace, CEO of Accelerate Brain Cancer Cure. "I am honored to serve as a member of PBTF's distinguished panel of advisors."

PBTF is the world's largest nonprofit funder of research into one of the deadliest forms of childhood cancer - investing more than $24 million in cutting-edge medical research to date. More than 28,000 children in the United States are living with the diagnosis of a brain tumor, and 13 more cases are identified each day.